I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

04 Feb

I-Mab logo-EN.png

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35^th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.

Details are as follows:

Oppenheimer’s 35^th Annual Healthcare Life Sciences Conference
Conference Date:		February 11-12, 2025
Format:		Company Presentation and one-on-one meetings
Presentation Time:		Tuesday, February 11, 2025, 4:00 to 4:30 PM ET
Webcast Link:		https://wsw.com/webcast/oppenheimer39/imab/2739496

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.

Investor & Media Contacts

PJ Kelleher
LifeSci Advisors
+1 617-430-7579
pkelleher@lifesciadvisors.com

IR@imabbio.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2508345580"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508345580\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2508345580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-04 20:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2508345580","market":"us","top_or_hot":-1,"title":"I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/y0il.Wp4rkHlUptHFsH61w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/61ac48be92843ad3a8f6edb37f7d267b\" title=\"I-Mab logo-EN.png\" vspace=\"5\"/>\n<p>ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35<sup>th</sup> Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.</p>\n<p>Details are as follows:</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"3\"><strong>Oppenheimer’s 35</strong><sup><strong>th</strong></sup><strong> Annual Healthcare Life Sciences Conference</strong></td>\n</tr>\n<tr>\n<td>Conference Date:</td>\n<td> </td>\n<td>February 11-12, 2025</td>\n</tr>\n<tr>\n<td>Format:</td>\n<td> </td>\n<td>Company Presentation and one-on-one meetings</td>\n</tr>\n<tr>\n<td>Presentation Time:</td>\n<td> </td>\n<td>Tuesday, February 11, 2025, 4:00 to 4:30 PM ET</td>\n</tr>\n<tr>\n<td>Webcast Link:</td>\n<td> </td>\n<td>https://wsw.com/webcast/oppenheimer39/imab/2739496</td>\n</tr>\n</tbody>\n</table>\n<p><strong>About I-Mab</strong></p>\n<p>I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.</p>\n<p><strong>Investor &amp; Media Contacts</strong></p>\n<p>PJ Kelleher<br/>LifeSci Advisors<br/>+1 617-430-7579<br/>pkelleher@lifesciadvisors.com<br/><br/><br/></p>\n<p>IR@imabbio.com</p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nI-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-04 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mab-present-oppenheimer-35th-annual-123000412.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mab-present-oppenheimer-35th-annual-123000412.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPY","symbol_name":"奥本海默控股","start_time":0,"source_url":"https://finance.yahoo.com/news/mab-present-oppenheimer-35th-annual-123000412.html","article_id":"2508345580","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508345580","pubTimestamp":1738672200,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"I-Mab  is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPY":"奥本海默控股","QLD":"纳指两倍做多ETF","BK4139":"生物科技","USAW.SI":"AMZN 3xLongSG261006","BK4137":"综合支持服务","PSQ":"纳指反向ETF","BK4535":"淡马锡持仓","IMAB":"天境生物","TSYW.SI":"TESLA 3xLongSG261006","USJW.SI":"ALPHAB 3xLongSG261006","SQQQ":"纳指三倍做空ETF","BK4526":"热门中概股","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite","BK4505":"高瓴资本持仓","HCSG":"医疗保健服务","TQQQ":"纳指三倍做多ETF","BK4127":"投资银行业与经纪业","NVIW.SI":"NVDA 3xLongSG261006"},"translate_title":"天境生物将出席奥本海默第35届年度医疗保健生命科学会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.67,"MNQmain":0.6,"NQmain":0.6,"HCSG":1,"IMAB":0.9,"NVIW.SI":0.6,"OPY":1,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"USJW.SI":0.6},"content_text":"ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.\nDetails are as follows:\n\n\n\nOppenheimer’s 35th Annual Healthcare Life Sciences Conference\n\n\nConference Date:\n \nFebruary 11-12, 2025\n\n\nFormat:\n \nCompany Presentation and one-on-one meetings\n\n\nPresentation Time:\n \nTuesday, February 11, 2025, 4:00 to 4:30 PM ET\n\n\nWebcast Link:\n \nhttps://wsw.com/webcast/oppenheimer39/imab/2739496\n\n\n\nAbout I-Mab\nI-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.\nInvestor & Media Contacts\nPJ KelleherLifeSci Advisors+1 617-430-7579pkelleher@lifesciadvisors.com\nIR@imabbio.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}